Details for Patent: 8,076,515
✉ Email this page to a colleague
Which drugs does patent 8,076,515 protect, and when does it expire?
Patent 8,076,515 protects XADAGO and is included in one NDA.
This patent has fifty-three patent family members in twenty-six countries.
Summary for Patent: 8,076,515
| Title: | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides |
| Abstract: | A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to catalytic hydrogenation in the presence of a heterogeneous catalyst in a protic organic solvent. |
| Inventor(s): | Barbanti; Elena (Cologno Monzese, IT), Caccia; Carla (Cardano Al Campo, IT), Salvati; Patricia (Arese, IT), Velardi; Francesco (Cameri, IT), Ruffilli; Tiziano (Vigliano Biellese, IT), Bogogna; Luigi (Vaprio D'Agogna, IT) |
| Assignee: | Newron Pharmaceuticals S.p.A. (Bresso, IT) |
| Application Number: | 12/338,825 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,076,515 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; Compound; Process; |
Drugs Protected by US Patent 8,076,515
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-001 | Mar 21, 2017 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING 'OFF' EPISODES | ⤷ Sign Up | |
| Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-002 | Mar 21, 2017 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING 'OFF' EPISODES | ⤷ Sign Up | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,076,515
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 06012565 | Jun 19, 2006 | |
International Family Members for US Patent 8,076,515
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 061510 | ⤷ Sign Up | |||
| Australia | 2007263328 | ⤷ Sign Up | |||
| Brazil | PI0712936 | ⤷ Sign Up | |||
| Canada | 2653012 | ⤷ Sign Up | |||
| China | 101472880 | ⤷ Sign Up | |||
| China | 103284984 | ⤷ Sign Up | |||
| Cyprus | 1115951 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
